Abdulrahman M, Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE et al . 2007 Indentification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene. Mar 8; 26 (11): 1661-72
Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R. 2007 Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. Oct 10;25(29):4603-9.
Arraras JI, Kuljanic-Vlasic K, Bjordal K, Yun YH, Efficace F, Holzner B et al 2006. EORTC QLQ-INFO26: A questionnaire to assess information given to cancer patients. A preliminary analysis in eight countries. Psycho Oncology. Mar; 16 (3) 249-54
Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby P 2007. Key Clinical Issues in Renal Cancer - A Challenge for Proteomics. World Journal of Urology. Dec; 25 (6): 537-556
Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. 2007 A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. Jan 15;96(1):29-37. Epub 2006 Dec 19.
Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE.2007 High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene. Sep 10; [Epub ahead of print]
Bottley G, Cook GP, Blair GE. 2007 A flow cytometric assay for analysis of natural-killer cell-mediated cytolysis of adenovirus-transformed cells. Methods Mol Med. 131:221-30.
Braun MS, Quirke P, Seymour MT 2007 Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Reviews of Anticancer Therapy 7: 489-501.
Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F et al 2007 Molecular predictors of benefit from oxaliplatin and irinotecan in a large randomized trial in advanced colorectal cancer. International Journal of Cancer. Apr; 7(4): 489-501
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, P PO et al. 2007 Prolonged Efficacy Of A Single Dose Of The Bisphosphonate Zoledronic Acid: Implications For Management Of Bone Loss In Cancer Patients. Clinical Cancer Research. Sep 15; 13 (18 Pt1): 5406-10
Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN et al. 2007 The Use Of Bone Markers In A Six Week Study To Assess The Efficacy Of Oral Clodronate In Patients With Metastatic Bone Disease. Calcified Tissue International. 2007 Nov; 81(5): 341-51
Chow E, Harris K, Tharmalingam S, Bezjak A, Wu J, Barton M, Eek R, Shafiq J, Velikova G, Bottomley A; on behalf of the EORTC-QLG Bone Metastases Module Development Group. 2007 Early phase in the development of a bone metastases quality of life module. Clin Oncol (R Coll Radiol). Apr;19(3 Suppl):S26
Cocks, K; Cohen, D; Wisloff, F; Sezer, O; Lee, S; Hippe, E; et al. 2007 An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma Euro J Cancer 43(11):1670-1678
Collinson FJ, Hall GD, Perren TJ, Jayson GC. 2008 Development of antiangiogenic agents for ovarian cancer. Expert Rev Anticancer Ther. Jan;8(1):21-32
Craven, I; Crellin, A; Cooper, R; Melcher, A; Byrne, P; Sebag-Montefiore, D. 2007 Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. British Journal of Cancer 97:1333-7
Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V et al 2007. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in 5 the context of a phase III clinical trial Annals of Oncology. Jun; 18(6): 997-1003
Downing A, Prakash K, Gilthorpe MS, Mikeljevic JS, Forman D. 2007 Socioeconomic background in relation to stage at diagnosis, treatment and survival in women with breast cancer. British Journal of Cancer Mar 12; 96(5): 836-40
Downing A, Stefoski Mikeljevic J, Haward RA, Forman D 2007. Variation in the treatment of cervical cancer patients and the effect of consultant workload on survival: a population-based study. European Journal Cancer Jan; 43(2): 363-70
El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP. 2007 The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. Sep 15;67(18):8444-9.
Ferguson RE, Hochstrasser DF, Banks RE 2007. Impact of pre-analytical variables on the analysis of biological fluids in proteomic studies. Proteomics- Clinical Applications Aug. Vol 1 Issue 8. No 8. Pages 739-746
Feyler, S; Prince, H.M; Towlsen, K; Nivison-Smith, I; Schey, S; Gibson, J; Patton, N; Bradstock, K; Marks, D.I; Cook, G. 2007 The role of high dose therapy and stem cell rescue in the management of T-cell malignant lymphomas (PTCL): A BSBMT and ABMTRR collaborative study Bone Marrow Transplantation 40(5):443-450
Fisher, S; Donnelly, A; Newsham, A; Johnston, C; Smith, A; Selby, P; et al. 2007 Individual assessment of quality of life: a communication tool for modern practice Oral Oncology 2(1):92-93
Georgopoulos NT, Merrick A, Scott N, Selby PJ, Melcher A, Trejdosiewicz LK. 2007 CD40 expression in colorectal cancer: a potential target for inflammatory tumour cell killing. International Journal of Cancer 121: 1373-1381
Grigg, R, Inman M, Kilner C, Koppen I, Marchbank J, Selby P, Sridharan V. Synthesis of carbo- and heterocycles via palladium catalysed cascade allene insertion-nucleophile incorporation-Michael addition processes. Tetrahedron: 63(27):6152-6169
Harrop, R; Drury, N; Shingler, W; Chikoti, P; Redchenko, I; Carroll, M.W; Kingsman, S.M; Naylor, S; Melcher, A; Nicholls, J; Wassan, H; Habib, N; Anthoney, A. 2007 Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clinical Cancer Research 13:4487-4494
Hewitt MJ, Anderson K, Hall GD, Weston M, Hutson R, Wilkinson N et al 2007. Women with peritoneal carcinomatosis of unknown origin: efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG : An International Journal of Obstetrics and Gynaecology Jan; 114(1): 46-50
Hill, Q.A; Buxton, D; Pearce, R; Gesinde, M.O; Smith, G.M; Cook, G. 2007 An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF Bone Marrow Transplantation 40(10):925-930
Hingorani, M; White, C.L; Agrawal, V.K; Vidal, L; Melcher, A; Harrington, K.J. 2007 Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting? Curr Cancer Drug Targets 7: 389-409
Hopkins TG, Marples M, Stark D 2007. Sunitinib in the management of gastrointestinal stromal tumours (GIST). European Journal of Surgical Oncology (Epub 12.12.07)
Iles MM 2007. Quantification and correction of bias in tagging SNPs caused by insufficient sample size and marker density by means of haplotype-dropping. Genetic Epidemiology 39: 1329-1337.
Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE. 2007 Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res. Dec 15;13(24):7370-9.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH.2007 Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients : A Study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 46(12):1051-1068.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH. 2007 Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res. Nov 1;13(21):6410-8.
Jong K, Marchiori E, van der Vaart A, Chin S F, Carvalho B, Tijssen M et al. 2007 Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors. Oncogene Mar 1; 26(10): 1499-506
Kottke, T; Sanchez-Perez, L; Diaz, R.M; Thompson, J; Chong, H; Harrington, K; Calderwood, S.K; Pulido, J; Georgopoulos, N; Selby, P; Melcher, A; Vile, R. 2007 Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer Cancer Res 67: 11970-11979
Mackay HJ, CJ Twelves 2007. Targeting the protien kinase C family: are we there yet? Nature Reviews Jul; 7(7): 554-62
Mackay HJ, Twelves CJ. Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; on behalf of the EORTC New Drug Development Group. 2008 A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. Apr;61(4):579-85. Epub 2007 May 23.
Marshall, L.C; Newsham, A; Smith, A; Wright, E.P; Velikova, G. 2007 Sexual difficulties in cancer patients: A longitudinal study Psycho-Oncology 16(3):S270-S271
McLintock, L.A; Cook, G; Holyoake, T.L; Jones, B.L; Kinsey, S.E; Jackson, G.H. 2007 High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in haematology patients Haematologica 92:572-573
Merrick, A; Diaz, R.M; O'Donnell, D; Selby, P; Vile, R; Melcher, A. 2007 Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy Cancer Immunol Immunother Dec 4 [Epub ahead of print]
Nsengimana Jrm, Nilesh S, Hall A, Balmforth A, Massimo M, Yuldasheva N et al. 2007. Enhanced linkage of a locus on chromosome 2 to premature coronary artery disease in the absence of hypercholesterolemia European Journal of Human Genetics Marc 01; 15: 313-319
Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ. 2007 An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer. Dec 27; [Epub ahead of print]
Perry SE, Robinson P, Melcher A, Quirke P, Bühring HJ, Cook GP, Blair GE. 2007 Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett. Mar 20;581(6):1137-42. Epub 2007 Feb 20.
Podmore, E.J; Marshall, L.C; Wright, P; Selby, P.J; Velikova, G. 2007 Routine assessment of social difficulties in cancer patients: Are we opening Pandora's box? Psycho-Oncology 16(9):S123-S124
Prestwich RJ, Errington F, Harrington KJ, Pandha HS, Selby PJ, Melcher AA. 2007 Oncolytic viruses: do they have a role in anti-cancer therapy? Clinical Medicine: Oncology
Rawstron, A.C; Jones, R.A; Ferguson, C; Hughes, G; Selby, P; Reid, C; Dalal, S; Howard, M; Smith, G; Hillmen, P; Owen, R.G; Jack, A.S. 2007 Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience Br J Haematol 139(5):845-8
Rees-Unwin KS, Craven RA, Davenport E, Hanrahan S, Totty NF, Dring AM et al 2007 Proteomic evaluation of pathways associated with dexamethasone mediated apoptosis and resistance in multiple myeloma. Br J Haematol 559-567.
Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold, James N et al 2007. Ovarian cancer is associated with changes in glycosylation in both acute phase proteins and IgG. Glycobiology 17: 1344-1356.
Scott, L; Soepenberg, O; Verweij, J; de Jonge, M.J; Th Planting, A.S; McGovern, D; Principe, P; Obach, R; Twelves, C.A. 2007 Multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol. Mar;18(3):569-75.
Seymour, M.T; Maughan, T.S; Ledermann, J.A; Topham, C; James, R; Gwyther, S.J; et al. 2007 Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet Jul 14; 370 (9582): 143-52
Seymour, M.T; Punt, C.J. CAIRO and FOCUS. Lancet. 2007 Dec 8;370(9603):1904-5; author reply 1905.
Seymour, M.T; Trigonis, I; Finan, P.J; Halstead, F; Dunham, R; Farrugia, D.C; et al. 2007 A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology. Jun 30
Smith, A; Wright, E.P; Selby, P; Velikova, G. 2007 Measuring social difficulties in routine patient centred assessment: A Rasch analysis of the Social Difficulties Inventory. Quality of Life Research 2007 16: 823-831.
Smith, A.B; Rush, R; Velikova, G; Wall, L; Wright, E.P; Stark, D; Selby, P; Sharpe, M. 2007 The initial development of an item bank to assess and screen for psychological distress in cancer patients. Psychooncology. 16(8):724-732
Smith, A.B; Wright, E.P; Selby, P; Velikova, G. 2007 A Rasch and Factor Analysis of the Functional Assessment of Cancer Therapy-General (FACT-G). Health and Quality of Life Outcomes 5:19.
Smith, I; Procter, M; Gelber, R.D; Guillaume, S; Feyereislova, A; Dowsett, M; et al. 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet Jan 6; 369(9555): 29-36
Smith, M.R; Cook, R.J; Coleman, R; Brown, J; Lipton, A; Major, P; et al. 2007 Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology Aug; 70(2): 315-9
Smith, A.B; Campbell, L; Selby, P.J; Brown, J; Velikova, G. 2007 Identifying levels of psychological distress prompting discussion & further action in oncology Psycho-Oncology 16(9):S126-S127
Smith, A.B; Campbell, L; Selby, P.J; Brown, J; Velikova, G. 2007 Predictors of changes in psychological well-being over time Psycho-Oncology 16(9):S241-S241
Smith, A.B; Wright, E.P; Selby, P.J; Velikova, G. 2007 The dimensional structure of the Functional Assessment of Cancer Therapy-General (FACT-G) Psycho-Oncology 16(3):274-274
Smith, A.B; Wright, E.P; Selby, P.J; Velikova, G. 2007 Agreement between the summary indices of the FACT-G and EORTC QLQ-C30: A preliminary analysis Psycho-Oncology 16(9):S241-S242
Stead, M.L; Fallowfield, L; Selby, P; Brown, J.M. 2007 Psychosexual function and impact of gynaecological cancer. Best Pract Res Clin Obstet Gynaecol 21(2):309-20.
Stein, K; Sugar, C; Velikova, G; Stark, D. 2007 Putting the “Q” in Quality Adjusted Life Years (QALYs) for advanced ovarian cancer – an approach using data clustering methods and the internet. European Journal Cancer. Jan;43(1):104-13
Strauss, R; Elliott, F; Affleck, P; Boon, A; Newton Bishop, J. 2007 A retrospective study addressed to understanding what predicts severe histological dysplasia/early melanoma in excised atypical melanocytic lesions British Journal of Dermatology Oct;157(4):758-64
Thanarajasingam, U; Sanz, L; Diaz, R; Qiao, J; Sanchez-Perez, L; Kottke, T; Thompson, J; Chester, J; Vile, R.G. 2007 Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 67:300-308
Twelves, C. 2007 Docetaxel weekly with metastatic breast cancer. Onkologie. Sep;30(8-9):407-8
Twelves, C. 2007 Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer? Nat Clin Pract Oncol. Nov 20; [Epub ahead of print]
Velikova, G; Awad, N; Coles-Gale, R; Wright, E.P; Brown, J.M; Selby, P.J. 2007 The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology. Nov 21; [Epub ahead of print]
Velikova, G; Weis, J; Hjermstad, M; Kopp, M; Morris, P; Watson, M; et al. 2007 The EORTC QLQ-HDC28: A supplementary module assessing the quality of life during and after highdose chemotherapy and stem cell transplantation. European Journal Cancer Jan; 43(1): 87-94
Velikova, G; Selby, P.J; Brown, J. 2007 Informing physicians of cancer patients quality of life (QOL) - Physicians' attitude, effects on communication and decision-making Psycho-Oncology 16(9):S6-S7
Velikova, G; Awad, N; Coles-Gale, R; Wright, E.P; Brown, J.M; Selby, P.J. 2007 The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views Psycho-Oncology
von Lilienfeld-Toal, M; Midgley,K ; Lieberbach, S; Barnard, L; Glasmacher, A; Gilleece M; Cook, G. 2007 Observation-based early warning scores to detect impending critical illness predicts in-hospital and overall survival in patients undergoing Allogeneic stem cell transplantation Biology of Bone Marrow Transplantation 13(5):568-576
von Lilienfeld-Toal, M; Gilleece, M; Cook, G. 2007 Systemic Toxoplasmosis post-Allogeneic stem cell transplantation (Allo-SCT): Lesson’s learned from HIV? Biology of Bone Marrow Transplantation13(7): 871-872
White, C.L; Menghistu, T; Twigger, K.R; Searle, P.F; Bhide, S.A; Vile, R.G; Melcher, A.A; Pandha, H. S; Harrington, K.J. 2007 Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo Gene Ther 15: 424-33
Wright, P; Smith, A.B; Roberts, K; Selby, P.J; Velikova, G.2007 Patient-centered assessment using the Social Difficulties Inventory (SDI): Guidance for staff Psycho-Oncology 16(9):S9-S10
Wright, P; Smith, A; Roberts, K; Selby, P; Velikova, G. 2007 Screening for social difficulties in cancer patients: clinical utility of the Social Difficulties Inventory Br J Cancer 97(8):1063-70
Agrawal, V.K; Copeland, K.M; Barbachano, Y; Rahim, A; Seth, R; White, C.L; Hingorani, M; Nutting, C.M; Kelly, M; Harris, P; Pandha, H; Melcher, A.A; Vile, R.G; Porter, C; Harrington, K.J. 2008 Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene Therapy Sep 11 [Epub ahead of print]
Albertella, M.R; Loadman, P.M; Jones, P.H; Phillips R.M; Rampling, R; Burnet, N; Alcock, C; Anthoney, A; Vjaters, E; Dunk, C.R; Harris, P.A; Wong, A; Lalani, A.S; Twelves, C.J. 2008 Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14(4):1096-104
Allan, J.M; Shorto, J; Adlard, J; Bury, J; Coggins, R; George, R; Katory, M; Quirke, P; Richman, S; Scott, D; Scott, K; Seymour, M; Travis, L.B; Worrillow, L.J; Bishop, D.T; Cox, A. 2008 UK NCRI Colorectal Clinical Studies Group. MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 123: 2456-9
Banks, R.E.2008 Preanalytical Influences in Clinical Proteomic Studies: Raising Awareness of Fundamental Issues in Sample Banking. Clin Chem. Jan;54(1):6-7
Bartlett, J.M; Munro, A; Cameron, D.A; Thomas, J; Prescott, R; Twelves, C.J. 2008 Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26(31):5027-35
Barrett, J.H; Cairns, D.A. 2008 Application of the Random Forest classification method to peaks detected from mass spectrometric proteomic profiles of cancer patients and controls. Stat. Applcns. Genet. Mol. Biol 7:2-4
Blair, G.E; Cook, G.P. 2008 Cancer and the immune system; an overview. Oncogene 27:5868
Bonney, G.K; Craven, R.A; Prasad, R; Melcher, A; Selby, P.J; Banks, R.E. 2008 Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 9: 149-158
Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE.2008 High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene. 27:1792-1799
Boxall, S.A; Cook, G.P; Pearce, D; Bonnet, D; El-Sherbiny, Y.M; Blundell, M.P; Howe, S.J; Leek, J.P; Markham, A.F; de Wynter, E.A. 2008 Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells. Bone Marrow Transplantation, in press (PubMedID: 18997827)
Braun, M.S; Richman, S.D; Quirke, P; Daly, C; Adlard, J.W; Elliott, F; Barrett, J.H; Selby, P; Meade, A.M; Stephens, R.J; Parmar, M.K.B; Seymour, M.T; on behalf of the MRC FOCUS (CR08) trial collaborators and the National Cancer Research Institute Colorectal Clinical Studies Group. 2008 Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from a large randomized trial J Clin Oncol 26(16):2690-8
Cairns, D.A; Perkins, D.N; Stanley, A.J; Thompson, D; Barrett, J.H; Selby, P.J; Banks, R.E. 2008 Integrated multi-level quality control for proteomic profiling studies using mass spectrometry BMC Bioinformatics 9(1):519
Cairns, D.A; Thompson, D; Perkins, D.N; Stanley, A.J; Selby, P; Banks, R.E. 2008 Proteomic profiling using mass spectrometry - does normalising by total ion current potentially mask some biological differences? Proteomics. Jan;8(1):21-7
Church, L.D; Cook, G.P; McDermott, M.F.2008 Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. Jan;4(1):34-42
Clamp, A.R; Schöffski, P; Valle, J.W; Wilson, R.H; Marreaud, S; Govaerts, A.S; Debois, M; Lacombe, D; Twelves, C; Chick, J; Jayson, G.C. 2008 EORTC New Drug Development Group. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 61(4):579-85
Coleman, R.E; Brown, J.E; Terpos, E; Lipton, A; Smith, M.R; Cook, R; Major P. 2008 Prognostic value of bone markers in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews 34:629-639
Comins, C; Heinemann, L; Harrington, K; Melcher, A; De Bono, J; Pandha, H. 2008 Reovirus: Viral Therapy for Cancer 'as Nature Intended'. Clinical Oncology Jun 24. [Epub ahead of print]
Eggermont, A.M; Suciu, S; Santinami, M; Testori, A; Kruit, W.H; Marsden, J; Punt, C.J; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Hauschild, A; Musat, E; Spatz, A; Keilholz, U; EORTC Melanoma Group. 2008 Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 12: 372(9633):117-26
Errington, F.E; White, C.L; Twigger, K.R; Rose, A; Scott, K; Steele, L; Ilett, L.J; Prestwich, R; Pandha, H.S; Coffey, M; Selby, P; Vile, R; Harrington, K.J; Melcher, A.A. Inflammatory Tumour Cell Killing By Oncolytic Reovirus For The Treatment Of Melanoma Gene Ther 15(18):1257-70.
Errington, F; Steele, L; Prestwich, R; Harrington, K; Pandha, H; Vidal, L; de Bono, J; Selby, P; Coffey, M; Vile, R; Melcher, A. 2008 Reovirus Activates Human Dendritic Cells To Promote Innate Anti-Tumor Immunity. The Journal of Immunology 180:6018-6026.
Feyler, F; O’Connor, S.J.M; Rawstrom, A.C; Subash, C; Ross, F; Pratt, G; Drayson, M.T; Cook, G; Ashcroft, J; Owen, R.G. 2008 IgM Myeloma: Arare entity characterized by a CD20-CD56-CD117- immunophenotype and thet(11;14) British Journal of Haematology 140(5):547-551
Folprecht, G; Seymour, M; Saltz, L; Douillard, J; Hecker, H; Stephens, R; Maughan, T; Van Cutsem, E; Rougier, P; Mitry, E; Schubert, U; Kohne, C. 2008 Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients with Metastatic Colorectal Cancer: combined analysis of 2,691 patients in randomised controlled trials. J of Clin Onco 26: 1443-51
Folprecht, G; Seymour, M; Saltz, L; Douillard, J; Hecker, H; Stephens, R; Maughan, T; Van Cutsem, E; Rougier, P; Mitry, E; Schubert, U; Kohne, C. 2008 Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients with Metastatic Colorectal Cancer: combined analysis of 2,691 patients in randomised controlled trials. J of Clin Onco 26: 1443-51
Gong,Y; Torres-Sanchez L; Lopez-Carrillo, L; Peng J; Sutcliffe A.E;1 White K.L;1 Humpf H; Turner P.C; Wild C.P. 2008 Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. Cancer Epidemiol. Biomarkers Prev 17:688-694
Hall, P.S; Kancherla, K; Sastry, P.S; Brown, J.E. 2008 Severe epistaxis with tyrosine kinase inhibitors. Clin. Oncol. (R Coll Radiol) 20:318- 319
Haller, D.G; Cassidy, J; Clarke, S.J; Cunningham, D; Van Cutsem, E; Hoff, P.M; Rothenberg, M.L; Saltz, L.B; Schmoll, H.J; Allegra, C; Bertino, J.R; Douillard, J.Y; Gustavsson, B.G; Milano, G; O'Connell, M; Rustum, Y; Tabernero, J; Gilberg, F; Sirzén, F; Twelves, C. 2008 Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26(13):2118-2123
Harrington, K.J; Melcher, A; Vassaux, G; Pandha, H.S; Vile, R.G. 2008 Exploiting synergies between radiation and oncolytic viruses. Current Opinion in Molecular Therapy 10:362-70
Hatfield, P; Merrick, A.E; West, E; O'Donnell, D; Selby, P; Vile, R; Melcher, A.A. 2008 Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 31: (7):620-632
Hénin, E; You, B; Vancutsem, E; Hoff, P; Cassidy, J; Twelves, C; Zuideveld, K; Sirzen, F; Dartois, C; Freyer, G; Tod, M; Girard, P. 2008 A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clin Pharmacol Ther. 2008 Dec 10 [Epub ahead of print]
Hennig, I.M; Naik, J.D; Brown, S; Szubert, A; Anthoney, D.A; Jackson, D.P; Melcher, A; Crawford, S.M; Bradley, C; Brown, J.M; Seymour, M.T. 2008 Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil And Leucovorin. Journal of Clinical Oncology 26:3411-17
Hennig, I.M; Twelves, C. 2008 Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills? Eur J Cancer. 44(11):1493-6
Hill, K.S; Errington, F; Steele, L.P; Merrick, A; Morgan, R; Selby, P.J; Georgopoulos, N.T; O Donnell, D.M; Melcher, A.A. 2008 OK432-Activated Human Dendritic Cells Kill Tumor Cells Via CD40/CD40 Ligand Interactions. The Journal of Immunology. 181:3108-3115
Hill, Q.A; Hill, A; Collyns, T.A; Pearce, R.M; Cook, G. 2008 Similar lymphocyte recovery & CMV reactivation profile between reduced intensity conditioning with Alemtuzumab and myeloablative Allogeneic stem cell transplantation Bone Marrow Transplantation 41(8), 749-751
Hingorani, M; White, C.L; Merron, A; Peerlinck, I; Gore, M.E; Slade, A; Scott, S.D; Nutting, C.M; Pandha, H.S; Melcher, A.A; Vile, R.G; Vassaux, G; Harrington, K.J. 2008 Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Research 68:9771-8
Hingorani, M; White, C.L; Zaidi, S; Merron, A; Peerlinck, I; Gore, M.E; Nutting, C.M; Pandha, H.S; Melcher, A.A; Vile, R.G; Vassaux, G; Harrington, K.J. 2008 Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clinical Cancer Research 14:4915-24
Hirsh, V; Major, P.P; Lipton, A; Cook R.J; Langer, C.J; Smith, M.R; Brown, J.E; Coleman, R.E. 2008 Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228-236
Hopkins, T.G; Marples, M; Stark, D. 2008 Sunitinib in the management of gastrointestinal stromal tumours (GIST). European Journal of Surgical Oncology 34:844-850
Kottke, T; Diaz, R.M; Kaluza, K; Pulido, J; Galivo, F; Wongthida, P; Thompson, J; Willmon, C; Barber, G.N; Chester, J; Selby, P; Strome, S; Harrington, K; Melcher, A; Vile, R.G. 2008 Use of biological therapy to enhance both virotherapy and adoptive T-Cell therapy for cancer. Molecular Therapy 16:1910-8
Kottke, T; Galivo, F; Wongthida, P; Maria Diaz, R; Thompson, J; Jevremovic, D; Barber, G.N; Hall, G; Chester, J; Selby, P; Harrington, K; Melcher, A; Vile, R.G. 2008 Treg Depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy 16:1217-1226
Lester, J.E; Dodwell, D; Purohit O.P; Gutcher, S.A, Ellis, S.P; Thorpe, R, Horsman, J.M; Brown, J.E, Hannon, R.A; Coleman, R.E. 2008 Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res 14:6336-6342
Lim, Z,Y; Cook, G; Johnson, P.R; Parker, A.N; Zuckerman, M; Marks, D; Wiltshire, H; Mufti, G.J; Pagliuca, A. 2008 Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation Leuk Res, e-pub
Lipton, A; Cook, R; Coleman, R.E; Major, P; Terpos, E; Body, J-J; Smith, M.R; Brown, J.E; Garnero, P. 2008 Normalisation of bone markers and improved survival during zoledronic acid therapy. Cancer 113(1):193-201
Lipton, A; Cook, R; Saad, F; Major, P; Garnero, P; Terpos, E; Brown, J.E; Coleman, R.E. 2008 Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201
Merrick, A; Diaz, R.M; O'Donnell, D; Selby, P; Vile, R; Melcher, A. 2008 Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy Cancer Immunol Immunother 57:897-906
Nirmalan, N; Harnden, P; Selby, P; Banks, R. 2008 Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges Molecular Biosystems 4:(7):712-20
Patel, P.M; Sim, S; O'Donnell, D.O; Protheroe, A; Beirne, D; Stanley, A; Tourani, J.M; Khayat, D; Hancock, B; Vasey, P; Dalgleish, A; Johnston, C; Banks, R.E; Selby, P.J. 2008 An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer Eur J Cancer 44:216-23
Prestwich, R.J; Errington, F; Hatfield, P; Merrick, A.E; Ilett, E.J; Selby, P.J; Melcher, A.A. 2008 The Immune System - is it Relevant to Cancer Development, Progression and Treatment? Clin Oncol 20: 101-12
Prestwich, R.P; Errington, F; Ilett, E.J; Morgan, R; Scott, K; Kottke, T; Thompson, J; Morrison, E.E; Harrington, K.J; Pandha, H.S; Selby, P.J; Vile, R.G; Melcher, A.A. 2008 Tumor Infection By Oncolytic Reovirus Primes Adaptive Anti-Tumor Immunity. Clinical Cancer Research 14:7358-66
Prestwich, R.J; Harrington, K.J; Pandha, H.S; Vile, R.G; Melcher, A.A; Errington, F. 2008 Oncolytic viruses: a novel form of immunotherapy. Expert Reviews in Anticancer Therapy 8:1581-8
Prestwich, R.J; Harrington, K.J; Vile, R.G; Melcher, A.A. 2008 Immunotherapeutic Potential Of Oncolytic Virotherapy (Letter). Lancet Oncology 9:610-2 Prestwich, R.J; Scott, K; Merrick, A; Brown, J; Harnden, P; Whelan, P; Cartledge, J; O’Donnell, D; Pandha, H; Selby, P; Banks, R.E; Melcher, A.A. 2008 The feasibility of establishing an adjuvant autologous renal cell carcinoma vaccination program. BJU International Oct 24 [Epub ahead of print]
Prestwich, R; Vile, R; Melcher, A. 2008 Cancer immunotherapy (Letter). New England Journal of Medicine. New England Journal of Medicine 359:1072
Qiao, J; Kottke, T; Willmon, C; Galivo, F; Wongthida, P; Diaz, R. M; Thompson, J; Ryno, P; Barber, G.N; Chester, J; Selby, P; Harrington, K; Melcher, A; Vile, R.G. 2008 Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy Nat Med 14: 37-44
Qiao, J; Wang, H; Kottke, T; White, C; Twigger, K; Diaz, R.M; Thompson, J; Selby, P; de Bono, J; Melcher, A; Pandha, H; Coffey, M; Vile, R; Harrington, K. 2008 Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus Clin Caner Res 14: 259-269
Qiao, J; Wang, H; Kottke, T; Diaz, R.M; Willmon, C; Hudacek, A; Thompson, J; Parato, K; Bell, J; Naik, J; Chester, J; Selby, P; Harrington, K; Melcher, A; Vile, R.G. 2008 Loading Of Oncolytic Vesicular Stomatitis Virus Onto Antigen-Specific Tcells Enhances The Efficacy Of Adoptive T-Cell Therapy Of Tumors Gene Ther 15:604-616
Scarisbrick, J.J; Taylor, P; Holtick, U; Makar, Y; Douglas, K; Berlin, G; Juvonen, E; Marshall, S; Ryggen, K; Gosling, I; Leci, R; Saglam, S; Das-Gupta, E; Ellis, R; Watson, L; Shaw, C; Parry, E; Cook, G; Clark, F; Morris, C; Drake, M. 2008 U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease British Journal of Dermatol 158(4):659-678
Scott, G.B; Meade, J.L; Cook, G.P. 2008 Profiling killers; unravelling the pathways of human natural killer cell function. Briefings Functional Genomics and Proteomics 7:8-16
Seymour, M.T; Trigonis, I; Finan, P.J; Halstead, F; Dunham, R; Wilson, G; Farrugia, D; Chester, J.D; King, J; Brown, C.B; Slevin, M.L; Joel, S.P. 2008 A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. Eur J Surg Oncol, 34:403-9
Twelves, C.J. 2008 Defining the optimal schedule of drug administration: art or science? J Clin Oncol 26(11):1781-2
Twelves, C. 2008 Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer? Nat Clin Pract Oncol 5(2):72-3
Twelves, C; Trigo, J.M; Jones, R; De Rosa, F; Rakhit, A; Fettner, S; Wright, T; Baselga, J. 2008 Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 44(3):419-26
Twigger, K; Vidal, L; White, C.L; De Bono, J.S; Bhide, S; Coffey, M; Thompson, B; Vile, R.G; Heinemann, L; Pandha, H.S; Errington, F; Melcher, A.A; Harrington, K.J. 2008 Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy Clin Cancer Res 14: 912-923
Vasudev, N.S; Brown, J.E; Brown, S.R; Rafiq, R; Morgan, R; Patel, P.M; O'Donnell, D; Harnden, P; Rogers, M; Cocks, K; Anderson, K, Paul; A, Eardley; Selby, P; Banks, R. 2008 Prognostic factors in renal cell carcinoma: Association of pre-operative sodium concentration with survival Clinical Cancer Research 14: (6):1775-81
Vasudev, N.S; Ferguson, R.E; Cairns, D.A; Stanley, A.J; Selby, P.J; Banks, R.E. 2008 Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same? Proteomics 8: (23-24):5074-85
Velikova, G; Awad, N; Coles-Gale, R; Wright, E.P; Brown, J; Selby, P. 2008 The clinical value of quality of life assessment in oncology practice – a qualitative study of patient and physician views Psychooncology 17: (7):690-698
Vidal, L; Pandha, H.S; Yap, T.A; White, C.L; Twigger, K; Vile, R.G; Melcher, A; Coffey, M; Harrington, K.J; Debono, J.S. 2008 A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clinical Cancer Research 14:7127-37
von Lilienfeld-Toal, M; Hahn-Ast, C; Furkert, K; Hoffman, F; Naumann, R; Bargou, R; Cook, G; Glasmacher, A. 2008 A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma European Journal of Haematology 81: 247-252
White, C.L; Twigger, K.R; Vidal, L; De Bono, J.S; Coffey, M; Heinemann, L; Morgan, R; Merrick, A; Errington, F; Vile, R.G; Melcher, A.A; Pandha, H.S; Harrington, K.J. 2008 Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Therapy 15:911-920
Wright, E; Marshall, L; Smith, A; Velikova, G; Selby, P. 2008 Measurement and interpretation of social distress using the Social Difficulties Inventory (SDI) European Journal of Cancer 44: (11):1529-35
Zielinski, C.C; Awada, A; Cameron, D.A; Cufer, T; Martin, M; Aapro, M. 2008 The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer. Jan 10; [Epub ahead of print]
Problem Solving in Oncology. Eds O'Donnell D, Leahy M, Marples M, Protheroe A, Selby P. Clinical Publishing, Oxford, 2007